skip to main content

GLP-1 RA for Cardiorenal Protection — RACP Adult Medicine MCQ

Instant feedback + full explanation. One question, done properly.

HardNephrologyGLP-1 RA for Cardiorenal ProtectionRACP Adult Medicine

A 60-year-old man with type 2 diabetes, CKD stage G3b (eGFR 38 mL/min/1.73m²), and established cardiovascular disease is on metformin, empagliflozin, and perindopril. HbA1c is 58 mmol/mol. BMI is 34 kg/m². What additional agent provides the most cardiorenal benefit?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — GLP-1 receptor agonist (semaglutide)

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) provide cardiovascular benefit (SUSTAIN-6, LEADER, REWIND) and emerging renal benefit (FLOW trial: semaglutide reduced kidney disease progression by 24%). In a patient with established CVD, obesity, and CKD on SGLT2i, adding a GLP-1 RA provides additive cardiometabolic and renal benefits.

Reference: KDIGO – 2024 – CKD; ADS 2024; FLOW Trial